Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CTYX Curative Biotechnology	$0.01 +3.2%	$0.01	$0.00 ▼ $0.22	$3.81M	-33.99	3.01 million shs	45,210 shs
DRRX DURECT	$0.62 -3.9%	$0.63	$0.48 ▼ $1.84	$19.09M	0.59	85,351 shs	62,479 shs
ELEV Elevation Oncology	$0.38 +0.4%	$0.33	$0.22 ▼ $3.28	$22.61M	1.43	1.51 million shs	801,319 shs
LGVN Longeveron	$1.30 -1.5%	$1.41	$1.14 ▼ $6.40	$19.41M	0.22	1.50 million shs	312,082 shs

20 Stocks to Sell Now

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CTYX Curative Biotechnology	+3.27%	-11.87%	-24.62%	-34.88%	-48.42%
DRRX DURECT	0.00%	+13.68%	-0.42%	-28.49%	-60.58%
ELEV Elevation Oncology	0.00%	+19.32%	+27.32%	-28.36%	-88.64%
LGVN Longeveron	0.00%	+5.69%	-7.14%	-23.08%	-28.18%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CTYX Curative Biotechnology	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
DRRX DURECT	1.3351 of 5 stars	0.0	3.0	0.0	4.4	3.8	0.0	0.0
ELEV Elevation Oncology	3.5186 of 5 stars	4.0	5.0	0.0	0.0	2.2	1.7	0.6
LGVN Longeveron	3.4977 of 5 stars	3.6	5.0	0.0	0.0	2.0	1.7	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CTYX Curative Biotechnology	0.00	N/A	N/A	N/A
DRRX DURECT	2.00	Hold	N/A	N/A
ELEV Elevation Oncology	2.00	Hold	$3.39	787.01% Upside
LGVN Longeveron	3.25	Buy	$8.67	566.67% Upside

Current Analyst Ratings Breakdown

Latest CTYX, ELEV, DRRX, and LGVN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/10/2025	ELEV Elevation Oncology	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform
6/10/2025	ELEV Elevation Oncology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Neutral
6/9/2025	ELEV Elevation Oncology	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
6/9/2025	ELEV Elevation Oncology	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
3/27/2025	DRRX DURECT	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral
3/24/2025	ELEV Elevation Oncology	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Equal Weight	$5.00 ➝ $1.00
3/21/2025	ELEV Elevation Oncology	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Market Perform
3/21/2025	ELEV Elevation Oncology	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform	$9.00 ➝ $1.00
3/21/2025	ELEV Elevation Oncology	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
3/21/2025	ELEV Elevation Oncology	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Neutral	$10.00 ➝ $0.70
3/21/2025	ELEV Elevation Oncology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$6.00 ➝ $1.00

(Data available from 6/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CTYX Curative Biotechnology	N/A	N/A	N/A	N/A	N/A	N/A
DRRX DURECT	$1.86M	10.29	N/A	N/A	$0.50 per share	1.23
ELEV Elevation Oncology	N/A	N/A	N/A	N/A	$1.29 per share	N/A
LGVN Longeveron	$2.23M	8.72	N/A	N/A	$2.68 per share	0.49

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CTYX Curative Biotechnology	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
DRRX DURECT	-$27.62M	-$0.15	N/A	N/A	N/A	-198.58%	-300.62%	-65.17%	8/5/2025 (Estimated)
ELEV Elevation Oncology	-$45.70M	-$0.82	N/A	N/A	N/A	N/A	-59.73%	-40.05%	8/5/2025 (Estimated)
LGVN Longeveron	-$21.41M	-$6.28	N/A	N/A	N/A	-967.49%	-142.43%	-100.84%	8/13/2025 (Estimated)

Latest CTYX, ELEV, DRRX, and LGVN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/15/2025	Q1 2025	ELEV Elevation Oncology	-$0.20	-$0.24	-$0.04	-$0.24	N/A	N/A
3/26/2025	Q4 2024	DRRX DURECT	$0.06	-$0.06	-$0.12	$0.24	$6.91 million	$2.30 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CTYX Curative Biotechnology	N/A	N/A	N/A	N/A	N/A
DRRX DURECT	N/A	N/A	N/A	N/A	N/A
ELEV Elevation Oncology	N/A	N/A	N/A	N/A	N/A
LGVN Longeveron	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CTYX Curative Biotechnology	N/A	N/A	N/A
DRRX DURECT	N/A	0.71	0.60
ELEV Elevation Oncology	0.45	17.77	17.77
LGVN Longeveron	N/A	7.67	7.67

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CTYX Curative Biotechnology	N/A
DRRX DURECT	28.03%
ELEV Elevation Oncology	83.70%
LGVN Longeveron	10.01%

Insider Ownership

Company	Insider Ownership
CTYX Curative Biotechnology	N/A
DRRX DURECT	3.20%
ELEV Elevation Oncology	8.10%
LGVN Longeveron	11.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CTYX Curative Biotechnology	4	388.50 million	N/A	Not Optionable
DRRX DURECT	80	31.04 million	30.05 million	Optionable
ELEV Elevation Oncology	40	59.22 million	54.33 million	Optionable
LGVN Longeveron	20	14.93 million	12.00 million	Not Optionable

CTYX, ELEV, DRRX, and LGVN Headlines

Recent News About These Companies

Longeveron Inc. CEO Wa’el Hashad to Present at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

June 11, 2025 | nasdaq.com

Longeveron® to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

June 9, 2025 | globenewswire.com

Longeveron Inc. (NASDAQ:LGVN) Director Sells $13,000.00 in Stock

June 3, 2025 | insidertrades.com

Here's Why Longeveron (NASDAQ:LGVN) Must Use Its Cash Wisely

May 29, 2025 | finance.yahoo.com

Longeveron Inc. to Explore Partnership Opportunities for Alzheimer’s Stem Cell Therapy Program at BIO International Convention

May 22, 2025 | nasdaq.com

Longeveron Inc.

May 21, 2025 | marketwatch.com

Longeveron® to Attend BIO International Convention 2025

May 20, 2025 | globenewswire.com

Longeveron® Named XPRIZE Healthspan Semifinalist and Top 40 Milestone 1 Award Recipient

May 12, 2025 | globenewswire.com

Longeveron Inc. (LGVN) Q1 2025 Earnings Call Transcript

May 9, 2025 | seekingalpha.com

LGVN Entering Crucial Period in Great Shape

May 9, 2025 | msn.com

Roth MKM Remains a Buy on Longeveron (LGVN)

May 9, 2025 | theglobeandmail.com

Longeveron Inc (LGVN) Q1 2025: Everything You Need To Know Ahead Of Earnings

May 9, 2025 | finance.yahoo.com

Longeveron® Announces First Quarter 2025 Financial Results and Provides Business Update

May 9, 2025 | finance.yahoo.com

Longeveron® to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025

May 2, 2025 | globenewswire.com

Longeveron® Issues Letter to Shareholders Highlighting Corporate Strategy, Recent Progress and Key Priorities and Goals for 2025

April 23, 2025 | finance.yahoo.com

Longeveron Inc. CEO Shares 2024 Progress and Strategic Goals for 2025 in Shareholder Letter

April 22, 2025 | quiverquant.com

Longeveron Stock Short Interest Report | NASDAQ:LGVN | Benzinga

April 18, 2025 | benzinga.com

LGVN Announces Positive Alzheimer’s News

March 20, 2025 | msn.com

Longeveron® Announces Positive Type B Meeting with U.S. FDA Regarding Pathway to BLA for Laromestrocel (Lomecel-BTM) in Alzheimer’s Disease

March 20, 2025 | finance.yahoo.com

Longeveron (LGVN) Receives a Buy from Roth MKM

March 20, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 Defense Stocks That Will Profit From a Golden Dome
By Chris Markoch | May 30, 2025
View 3 Defense Stocks That Will Profit From a Golden Dome
Analysts Think These Stocks Could More Than Double in Value
By Nathan Reiff | May 23, 2025
View Analysts Think These Stocks Could More Than Double in Value
Intel’s Turnaround May Be the Best Bet No One’s Watching
By Jeffrey Neal Johnson | May 30, 2025
View Intel’s Turnaround May Be the Best Bet No One’s Watching
CrowdStrike’s Rally Faces a Test—Here’s Why That’s Good
By Chris Markoch | May 20, 2025
View CrowdStrike’s Rally Faces a Test—Here’s Why That’s Good
D-Wave Quantum Stock: Are Advantage2 Gains Here to Stay?
By Nathan Reiff | May 28, 2025
View D-Wave Quantum Stock: Are Advantage2 Gains Here to Stay?

CTYX, ELEV, DRRX, and LGVN Company Descriptions

Curative Biotechnology OTCMKTS:CTYX

$0.0098 +0.00 (+3.16%)

As of 06/13/2025

Curative Biotechnology, Inc. engages in the provision of software solutions for the healthcare market. Its products include MedFlash, electronic Personal Health Manager, Medical Alert, personal emergency response services, product and medical transcription, disease management, revenue cycle management, and medical consulting-billing. The company was founded by Jon Pevzner on July 29, 1995 and is headquartered in Boca Raton, FL.

DURECT NASDAQ:DRRX

$0.62 -0.03 (-3.91%)

As of 06/13/2025 04:00 PM Eastern

DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. It also offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine over three days in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in other countries. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Innocoll Pharmaceuticals Limited. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.

Elevation Oncology NASDAQ:ELEV

$0.38 +0.00 (+0.39%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$0.38 +0.00 (+0.08%)

As of 06/13/2025 07:41 PM Eastern

Elevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target. Its EO-3021 selectively delivers a cytotoxic payload directly to cancer cells expressing Claudin 18.2. Elevation Oncology, Inc. has a license agreement with CSPC Megalith Biopharmaceutical Co., Ltd. to develop and commercialize EO-3021. The company was formerly known as 14ner Oncology, Inc. and changed its name to Elevation Oncology, Inc. in February 2020. The company was incorporated in 2019 and is based in Boston, Massachusetts.

Longeveron NASDAQ:LGVN

$1.30 -0.02 (-1.52%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$1.33 +0.03 (+2.38%)

As of 06/13/2025 07:58 PM Eastern

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors. It is conducting Phase 1, Phase 1/2, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer's disease, and hypoplastic left heart syndrome. Longeveron Inc. was incorporated in 2014 and is headquartered in Miami, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time